Thomas W. Burke, MD, Oral History Interview, March 11, 2014

Major Topics Covered: Personal and educational background Military service A portrait of a clinician with an “entrepreneurial spirit” Research: combination therapies for gynecologic cancershttps://openworks.mdanderson.org/mchv_interviewsessions/1218/thumbnail.jp

Thomas W. Burke, MD, Oral History Interview, March 18, 2014

Major Topics Covered: Gynecologic Oncology at MD Anderson and multi-disciplinary care Development of multi-disciplinary care at MD Anderson Roles as Physician-in-Chief Developing MD Anderson support serviceshttps://openworks.mdanderson.org/mchv_interviewsessions/1219/thumbnail.jp

Thomas W. Burke, MD, Oral History Interview, April 29, 2014

Major Topics Covered: Developing networks to serve MD Anderson MD Anderson culture: changes and continuities amid growth MD Anderson’s financial challenges and strategies to navigate themhttps://openworks.mdanderson.org/mchv_interviewsessions/1220/thumbnail.jp

Oncolog, Volume 37, Issue 04, October-December 1992

Universal access to health care requires insurance reform, says AMA\u27s Painter Tissue conservation techniques for patients with vulvar cancerhttps://openworks.mdanderson.org/oncolog/1040/thumbnail.jp

Verapamil protects against progression of experimental chronic renal failure

Verapamil protects against progression of experimental chronic renal failure. Chronic administration of verapamil (Ver) decreases nephrocalcinosis and tubular ultrastructural abnormalities in the remnant model of chronic renal disease. In the present study, the effect of chronic Ver administration on renal function, renal histology and mortality after subtotal nephrectomy was examined. Fourteen days after staged subtotal nephrectomy rats were paired according to renal functional impairment, mean arterial pressure (MAP), and body weight. Rats were pair fed and received either Ver (0.1 µg/g sc bid, N = 10) or saline (0.1ml sc bid, N = 10) for up to 23 weeks. Both members of each pair were sacrificed shortly before the uremic death of controls. At sacrifice, rats treated with Ver had a lower serum creatinine (2.29 vs. 2.99 mg/dl, P < 0.05) and a higher creatinine clearance (318 vs. 164 µl/min, P < 0.05) than controls. In a second experiment, survival was superior in rats treated with Ver than in controls from week seven (P < 0.0025 by week 14). Serum creatinine was higher at week 10 in control rats (1.68 vs. 1.10 mg/dl, P < 0.05). MAP was no different between the two groups, irrespective of the time between Ver administration and the measurement of MAP. Histological damage and nephrocalcinosis were worse, and renal and myocardial calcium content was higher in controls. In conclusion, independent of any effect on systematic MAP, chronic administration of Ver protects against renal dysfunction, histological damage, nephrocalcinosis and myocardictl calcification, and improves survival in the remnant model of chronic renal disease

The Legality of Collecting and Disclosing Patient Race and Ethnicity Data

This policy brief weighs whether the collection of patient data by race or ethnicity, as part of a program of quality improvement, violates the law

The Legality of Collecting and Disclosing Patient Race and Ethnicity Data

This policy brief weighs whether the collection of patient data by race or ethnicity, as part of a program of quality improvement, violates the law